[Current status of prevention of endogenous affective diseases using lithium].
D000342:Affective Symptoms / Q000188:drug therapy* / Q000517:prevention & control; D001290:Attitude; D001714:Bipolar Disorder / Q000188:drug therapy; D001835:Body Weight; D005260:Female; D006801:Humans; D008094:Lithium / Q000008:administration & dosage / Q000009:adverse effects / Q000097:blood / Q000506:poisoning / Q000627:therapeutic use*; D008134:Long-Term Care; D008297:Male; D010259:Paranoid Disorders / Q000188:drug therapy; D010919:Placebos; D011041:Poisoning / Q000517:prevention & control / Q000628:therapy; D011141:Polyuria / Q000139:chemically induced; D011247:Pregnancy; D011379:Prognosis; D012008:Recurrence; D013997:Time Factors; D014202:Tremor / Q000139:chemically induced
D010919:Placebos; D008094:Lithium
Heutiger Stand der Lithium-Rezidivprophylaxe bei endogenen affektiven Erkrankungen